Cutaneous leishmaniasis: Review Article-Reference-Cited by-同舟云学术

Cutaneous leishmaniasis: Review Article

Published:2023-04-08 Issue:2 Volume:2 Page:44-49
ISSN:2583-4053
Container-title:Journal for Research in Applied Sciences and Biotechnology
language:
Short-container-title:J. Res. Appl. Sci. Biotechnol.

Author:

Al-Ma'amouri May Y.

Abstract

Leishmaniasis is a protozoal infection caused by a number of different species in the Leishmania genus. Sandflies are the vectors for the transmission of these protozoa to humans. When macrophages are triggered into a leishmanicidal state, a clinical recovery occurs. In particular, the T-helper cell type 1 (Th1) response is responsible for this, and it is also responsible for preventing the recurrence of latent chronic infection. Regardless of the disease's clinical manifestation, antimonial drugs are the treatment of choice. Amphotericin B is the second-best treatment option. This study focuses on the pathology and treatment of cutaneous leishmaniasis.

Publisher

Stallion Publication

Reference24 articles.

1. S. H. Ralston, I. D. Penman, M. W. J. Strachan, and R. Hobson, Davidson’s Principles and Practice of Medicine E-Book. Elsevier Health Sciences, 2018.

2. M. S. Bailey and D. N. J. Lockwood, “Cutaneous leishmaniasis,” Clin. Dermatol., vol. 25, no. 2, pp. 203–211, 2007.

3. Z. Bezie et al., “Common skin diseases,” Int Dev, vol. 13, pp. 200–204, 2005.

4. A. O. Jawabreh, “RISK ASSESSMENT OF CUTANEOUS LEISHMANIASIS IN JERICHO CITY-PALESTINE.” Al-Quds University-Palestine, 1999.

5. H. J. C. de Vries, S. H. Reedijk, and H. D. F. H. Schallig, “Cutaneous leishmaniasis: recent developments in diagnosis and management,” Am. J. Clin. Dermatol., vol. 16, no. 2, pp. 99–109, 2015.